Business Daily Media

The Times Real Estate

.

Three simple things Australia should do to secure access to treatments, vaccines, tests and devices during the coronavirus crisis

  • Written by Deborah Gleeson, Senior Lecturer in Public Health, La Trobe University
image

Patents and related intellectual property rights can present formidable barriers to procuring medicines, vaccines, diagnostic tests and medical devices.

They can cost lives, particularly during a public health emergency.

Two examples from the United States illustrate the point.

The US conglomerate 3M holds hundreds of patents on N95 face masks[1]. The Governor of Kentucky has asked it to release them[2] so other manufacturers can make the masks.

Gilead Sciences holds a range of patents for remdesivir[3], one of the leading candidates for treating COVID-19.

Read more: Drug companies should drop their patents and collaborate to fight coronavirus[4]

It recently applied for an extra period of exclusivity[5] which would have extended the length of time other firms were prevented from manufacturing the drug without its permission. It withdrew[6] its application after a public outcry.

In the past few weeks 150 civil society organisations, including Médecins Sans Frontières[7], have called on Gilead to forgo its patents.

There are three things Australia should do to manage these sorts of situations.

1. Prepare to over-ride patents

First, Australia should prepare to take advantage of some rarely-used but vitally important safeguards in the Commonwealth Patents Act[8].

They enable patents to be over-ridden when necessary to prevent shortages of vital medical supplies.

Under Sections 132-133, the Federal Court can order that a compulsory license be granted for a patented invention, meaning that a third party (such as a company that produces generic medicines or face masks) can manufacture copies of the invention without the permission of the patent owner.

This can be done under conditions outlined in Section 133, Para 3[9], which include that

  • demand in Australia for the original invention is not being met on reasonable terms

  • authorisation to exploit the original invention is essential to meet that demand

  • the applicant has tried for a reasonable period, but without success, to obtain authority from the patentee to exploit the original invention on reasonable terms and conditions

  • the patentee has given no satisfactory reason for failing to exploit the patent to the extent necessary to meet the demand for the original invention in Australia

Although the requirement that the applicant has tried for a reasonable period without success to obtain authority can slow down the process, the World Trade Organisation’s Agreement on Trade-Related Intellectual Property Rights[10] allows for legislation that bypasses the need for negotiations in an emergency.

Last month Canada[11] passed such legislation, specifying that it was for the period of the coronavirus emergency.

Read more: Canada's coronavirus aid package guards against drug shortages with compulsory licensing[12]

Australia should consider doing the same.

The Patent Act’s crown use[13] provisions (Sections 163-170) provide another (potentially easier) mechanism allowing Australian governments to over-ride a patent in an emergency in order to provide a service primarily provided or funded by a government.

These provisions could also be redrafted to reduce ambiguity and make them easier to use in an emergency.

Using these provisions, particularly if they are made more workable, could mean that medical technologies could be manufactured locally if there are shortages or if they are not available from the patent holder at a reasonable price.

2. Reinstate the right to import low-cost medicines

Australia should also reverse its earlier decision to voluntarily waive[14] its right to import medicines manufactured in another country under a compulsory license.

If Australia doesn’t have the manufacturing capacity to produce a particular drug, or to produce enough of it to meet its population’s needs, it should be able to import a low-cost version from another country.

To reverse the waiver, the Australian Government needs to notify[15] the World Trade Organization that it has changed its policy and now considers itself an eligible importing country, at least in the context of an emergency.

3. Support Costa Rica’s proposal for a global COVID-19 pool

Finally, the Australian Government should follow The Netherlands[16] in supporting Costa Rica’s[17] proposal for a World Health Organization global pool for rights on data and knowledge that can be of use for the prevention, detection and treatment of COVID-19.

Now put forward by the European Union[18] as a draft resolution for the World Health Assembly, the initiative aims to provide free access to existing knowledge about diagnostic tests, devices, drugs and vaccines, enabling all countries to quickly access or produce affordable products.

Read more: Supplies needed for coronavirus healthcare workers: 89 million masks, 30 million gowns, 2.9 million litres of hand sanitiser. A month.[19]

Each of three simple practical actions could prevent intellectual property rights from becoming an insurmountable barrier to accessing essential products during the emergency.

References

  1. ^ N95 face masks (www.msn.com)
  2. ^ release them (www.courier-journal.com)
  3. ^ remdesivir (www.drugs.com)
  4. ^ Drug companies should drop their patents and collaborate to fight coronavirus (theconversation.com)
  5. ^ extra period of exclusivity (www.npr.org)
  6. ^ withdrew (www.gilead.com)
  7. ^ Médecins Sans Frontières (msfaccess.org)
  8. ^ Patents Act (www5.austlii.edu.au)
  9. ^ Section 133, Para 3 (www5.austlii.edu.au)
  10. ^ Agreement on Trade-Related Intellectual Property Rights (www.wto.org)
  11. ^ Canada (theconversation.com)
  12. ^ Canada's coronavirus aid package guards against drug shortages with compulsory licensing (theconversation.com)
  13. ^ crown use (www5.austlii.edu.au)
  14. ^ voluntarily waive (www.keionline.org)
  15. ^ notify (www.keionline.org)
  16. ^ The Netherlands (www.healthpolicy-watch.org)
  17. ^ Costa Rica’s (www.presidencia.go.cr)
  18. ^ European Union (www.statnews.com)
  19. ^ Supplies needed for coronavirus healthcare workers: 89 million masks, 30 million gowns, 2.9 million litres of hand sanitiser. A month. (theconversation.com)

Authors: Deborah Gleeson, Senior Lecturer in Public Health, La Trobe University

Read more https://theconversation.com/three-simple-things-australia-should-do-to-secure-access-to-treatments-vaccines-tests-and-devices-during-the-coronavirus-crisis-136052

Cutting edge AI technology designed for doctors to reduce patient wait times launched in NZ

New Zealand specialist doctors now have access to Artificial Intelligence technology to help reduce patient wait times and experts say it could be...

Launchd Takes Off: Former AFL Stars Lead Tech-Powered Platform Set to Disrupt Talent and Influencer Marketing

Backed by Institutional Capital, Launchd Combines Five Leading Agencies and Smart Technology to Deliver Measurable Results Influencer marketing i...

Meet the Australian fintech unlocking rewards for small businesses

Small businesses make up 98 per cent of all businesses in Australia, yet they continue to bear the brunt of economic uncertainty. According to Credi...

Teleperformance (TP) Business Insights Report Reveals Key Shifts in Consumer Behaviour

TP’s Business Insights report  into consumer behaviors and preferences, taking in more than 57,000 respondents across 19 sectors, is shedding new li...

HubSpot launches platform-wide AI tools to help businesses close the adoption gap

HubSpot today unveiled more than 200 updates across its customer platform to help businesses grow better. The release introduces smarter tools, new AI...

Why Every Leader Needs a Personal Branding Strategy in 2025

One of the best investments you can make in 2025? Your Personal Brand.In today’s competitive and digitally driven business world, authenticity and...

Sell by LayBy